Kairos Pharma, Ltd. filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission on September 14, 2026. The filing discloses that the company issued a new investor presentation and is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference.
The conference is set to take place in New York, New York, from September 14 to September 16, 2026. As part of the event, Kairos Pharma’s Chief Executive Officer, John Yu, will present the investor presentation to provide an update on the company’s clinical program and activities.
A copy of the investor presentation is being furnished as Exhibit 99.1 to the Form 8-K. The filing notes that the information included in this item is being furnished and shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934.
